Related Experiment Video
Updated: May 1, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
16.0K
[Immunological treatment options for schizophrenia]
N Müller1, D Krause1, E Weidinger1
1Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München.
Fortschritte Der Neurologie-Psychiatrie
|April 9, 2014
Summary
Schizophrenia involves immune dysfunction, leading to kynurenine acid (KYNA) buildup and reduced neurotransmission. Anti-inflammatory treatments targeting cyclo-oxygenase-2 (COX-2) show promise, especially in early schizophrenia stages.
Area of Science:
- Neuroscience
- Immunology
- Psychiatry
Context:
- Schizophrenia pathophysiology involves unclear dopaminergic dysfunction, with inflammation playing a key role.
- Type 1 immune response dysfunction decreases indolamine-2.3-dioxygenase (IDO) activity, increasing kynurenine acid (KYNA) and reducing glutamatergic neurotransmission.
- Neuroinflammation, involving microglial and astrocyte activation, contributes to TH1-TH2 immune imbalance.
Purpose:
- To explore the role of inflammation and immune responses in schizophrenia's dopaminergic dysfunction.
- To evaluate the impact of antipsychotics on immune balance and KYNA levels.
- To discuss the therapeutic potential of anti-inflammatory and immunomodulatory strategies in schizophrenia.
Summary:
- Dysfunctional immune responses in schizophrenia lead to increased kynurenine acid (KYNA) production, an NMDA antagonist, impacting neurotransmission.
- Antipsychotics, while D2 antagonists, exhibit immune effects that partially correct the type-1/type-2 imbalance and KYNA overproduction.
- Inflammation markers like prostaglandin E2 (PGE2) and cyclo-oxygenase-2 (COX-2) are elevated; COX-2 inhibitors show therapeutic benefits, particularly in early-stage schizophrenia.
Impact:
- Findings suggest anti-inflammatory therapies, especially COX-2 inhibitors, offer a promising avenue for schizophrenia treatment.
- Understanding the immune-neurotransmitter link provides a basis for developing novel immunomodulatory treatments for schizophrenia.
- Early intervention with anti-inflammatory agents may improve outcomes for schizophrenia patients.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
01:28Psychosis and Antipsychotic Drugs: Overview
1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
01:28Drug Therapy
449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
449
01:29Biological Causes of Schizophrenia
1.2K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:29Psychological and Sociocultural Causes of Schizophrenia
977
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
977